Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errors“Undruggable” small RNAs are not impossible to target; the term describes a drug-discovery challenge. A Chemistry World archive item dated 12 February 2014 described a synthetic strategy for creating small molecules aimed at small RNAs, with diseases such as cancer as possible applications. The available archive summary does not identify the RNA target, the precise strategy, or the study’s results, so it cannot establish that a treatment was developed.
What the 2014 headline actually establishes
The Chemistry World archive lists the item on 12 February 2014 and characterizes it as chemists turning the drug-discovery process “on its head” to create small molecules that could treat diseases such as cancer. That is an archive summary, not a verified account of the study’s exact method or findings. The original story and its primary paper are not available in the evidence retrieved for this article. Chemistry World
As an Amazon Associate I earn from qualifying purchases.
Consequently, the headline supports a narrow conclusion: researchers were pursuing a synthetic route to small molecules intended to target small RNAs. It does not identify which RNA was targeted, what molecules were made, what experiments were performed, or whether any molecule showed therapeutic effects. It also does not establish an approved medicine or a treatment recommendation.
Why small RNAs can be difficult drug targets
RNA is not a rigid, uniform surface. Its flexible structure and comparatively limited chemical diversity can make it hard to find a ligand that binds one RNA selectively rather than many others. Stable folds and particular structural elements may offer more recognizable binding features, but finding a binding interaction is only one step toward a useful drug.
#1 Best Overall
A 2022 review of RNA-binding macrocyclic peptides describes this broader challenge and outlines ways researchers have pursued RNA recognition. Its discussion provides context for the field; it does not show that the 2014 Chemistry World item involved macrocyclic peptides or used any of the methods below. Chemical Reviews: RNA-binding macrocyclic peptides
Three discovery routes discussed in a later review
The 2022 review groups work on RNA-binding macrocyclic peptides into three broad approaches. These are examples of research in the wider field, not confirmed details of the 2014 report.
Mimicking RNA-binding proteins
Researchers can draw on the ways natural RNA-binding proteins recognize RNA and use those interactions as a starting point for designing peptide ligands. The challenge is to reproduce useful recognition while achieving enough selectivity for a particular RNA structure.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Screening peptide libraries
Another route is to screen collections of peptides for RNA binding, then investigate promising candidates. A binding result alone does not show that a candidate enters cells, reaches the relevant intracellular location, or affects a disease process.
Adapting natural products
Natural products can provide molecular scaffolds for RNA-binding ligands. Adapting a scaffold still leaves the central development questions: whether the resulting molecule binds the intended RNA selectively and whether it can function in cells and, ultimately, in an organism.
Binding is not the same as a medicine
The review emphasizes the gap between biochemical binding and therapeutic readiness. Selectivity, cell permeability, intracellular distribution, and performance in animal models all matter. A molecule that binds RNA in an assay may fail to reach the right place in a living cell or may interact with other targets.
Rank #4
- Used Book in Good Condition
For the RNA-binding molecules covered by that review, the authors reported that animal experiments and clinical trials had not been reported for the examples they described, apart from some ribosome-targeting antibiotic peptides. This is a statement about that review’s set of examples at the time of publication—not every RNA-targeting program, and not evidence about the 2014 study.
What would be needed to judge the specific strategy
To evaluate the 2014 headline as a scientific claim, readers would need the original article or primary study. The key details to verify are the identity and structure of the RNA target, the synthetic discovery method, the molecules produced, and the experiments used to establish binding, selectivity, cellular activity, and any therapeutic relevance. Without those details, attributing a specific method or result to the report would go beyond the evidence.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
